Shares of Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) climbed steadily on Tuesday after the company disclosed that it plans to sell 16.4 million shares of common stock at $6.50 apiece to entities managed by the Baupost Group LLC. The hedge fund increased its stake in Idenix from 27 percent to approximately 35 percent of outstanding shares.